Valuation : Nectar Lifesciences Limited

Market Cap 2.36B 24.9M 21.41M 20.14M 18.38M 34.3M 34.47M 239M 92.32M 1.21B 93.49M 91.45M 3.84B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 1.11B 11.7M 10.06M 9.46M 8.64M 16.12M 16.2M 112M 43.38M 567M 43.94M 42.98M 1.8B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
08-15 Nectar Lifesciences Limited Changes Its Corporate Office in Chandigarh CI
08-14 Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 CI
08-14 Nectar Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-06 Nectar Lifesciences Limited Announces Resignation of Dr. Surulichamy Senthilkumar from Non-Executive Non-Independent Director, Effective August 06, 2026 CI
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
1 day+1.07%
1 week-1.60%
Current month-1.60%
1 month+15.94%
3 months+2.76%
6 months+4.15%
Current year-36.97%
1 week 11.71
Extreme 11.71
12.72
1 month 10.16
Extreme 10.16
13.4
Current year 9.2
Extreme 9.2
20.94
1 year 9.2
Extreme 9.2
22.49
3 years 9.2
Extreme 9.2
56.39
5 years 9.2
Extreme 9.2
56.39
10 years 7.2
Extreme 7.2
56.39
Manager TitleAgeSince
Director of Finance/CFO 68 2022-11-13
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 1995-06-26
Director/Board Member 69 2019-02-10
Director/Board Member 75 2021-09-20
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-1.60% - - 24.79M
-0.48%-4.98%+18.34%+66.44% 48.08B
+0.60%-3.67%+43.01%+112.23% 39.95B
-0.79%-1.79%-10.91%+10.78% 11.92B
-0.99%-1.36%+12.99%+80.96% 12.2B
-0.38%-0.76%+24.29%+137.27% 9.22B
-1.02%-4.04%+21.19%+33.90% 7.41B
+0.25%-1.06%+39.66%-12.93% 7.37B
+0.92%-0.22%+20.60%+211.71% 7.32B
-0.77%-2.60%-46.73%+21.08% 5.17B
Average -0.16%-1.87%+13.61%+73.49% 16.51B
Weighted average by Cap. -0.18%-3.02%+21.60%+79.89%

Financials

2025 2026
Net sales 16.7B 176M 151M 143M 130M 243M 244M 1.69B 653M 8.54B 662M 647M 27.17B -
Net income -1.14B -11.99M -10.31M -9.7M -8.85M -16.52M -16.6M -115M -44.46M -581M -45.03M -44.04M -1.85B -2.93B -30.89M -26.56M -24.99M -22.81M -42.56M -42.78M -296M -115M -1.5B -116M -113M -4.76B
Net Debt 5.62B 59.31M 50.99M 47.97M 43.78M 81.7M 82.13M 568M 220M 2.87B 223M 218M 9.15B -1.25B -13.2M -11.35M -10.67M -9.74M -18.18M -18.27M -126M -48.93M -639M -49.55M -48.47M -2.03B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
26-09-08 12.29 +1.07% 15,987
26-09-07 ₹12.16 -0.49% 19,641
26-09-04 ₹12.22 +0.58% 15,096
26-09-03 ₹12.15 -0.98% 9,226
26-09-02 ₹12.27 +1.40% 25,472
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!